About
Expertise in the discovery of novel targets and biomarkers for small molecule, antibody, and oligonucleotide-based therapeutic modalities.
Experience
-
Founder at Monoceros Biosystems
Mar 2017 - Present · 9 yrs 4 mos
-
Investor at NuFund Venture Group
Aug 2021 - Present · 4 yrs 11 mos
-
Co-Founder at DTxPharma
Jul 2017 - Jul 2023 · 6 yrs 1 mo
Acquired by Novartis in 2023
-
Sr. Director, Discovery Technologies and Orphan Diseases at Regulus Therapeutics
Jun 2012 - Feb 2017 · 4 yrs 9 mos
Acquired by Novartis in 2025
-
Senior Principal Scientist in Computational Biology at Pfizer
Jul 2006 - Jun 2012 · 6 yrs
Identification of new cancer targets and discovery of predictive biomarkers of drug response from multidimensional omics data